Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Vehicle-controlled, Multiple Cohort Study To Determine The Safety, Tolerability, And Pharmacokinetic Profile Of An2728 Ointment B, 2% In Healthy Volunteers And Patients With Mild-to-moderate Plaque-type Psoriasis

Next Previous
Trial Profile

A Randomized, Double-blind, Vehicle-controlled, Multiple Cohort Study To Determine The Safety, Tolerability, And Pharmacokinetic Profile Of An2728 Ointment B, 2% In Healthy Volunteers And Patients With Mild-to-moderate Plaque-type Psoriasis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crisaborole (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Anacor Pharmaceuticals

    • Most Recent Events

    • 20 May 2020 Results (n=244) assessing systemic exposure parameters of crisaborole with ointment dose and identifing covariates that impact the PK parameters of crisaborole in healthy participants and in patients with AD or psoriasis in 6 studies (C3291010, AN2728-PS-104, NCT01258088; C3291019, AN2728-TQT-108; C3291009, AN2728-PK-101; C3291007, AN27208-AD-203, NCT01652885; C3291006, AN2728-AD-102 & C3291012, AN2728-PSR-106), published in the Journal of Clinical Pharmacology.
    • 05 Feb 2011 Brief results in volunteers reported in an Anacor Pharmaceuticals media release.
    • 17 Dec 2010 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top